All In Biotech

Drug Trial Radar · NCT07503639

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

An Exploratory Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Based on Molecular Subtypes

Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Apr 2028

Study completion Apr 2030

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single-center, phase II umbrella trial designed to evaluate the efficacy and safety of neoadjuvant therapy for locally advanced colorectal cancer. Patients will be stratified into four cohorts based on microsatellite instability (MSI) status, KRAS mutation status, and the consensus molecular subtypes (CMS). Six arms are included across four cohorts and each arm will be assigned to a specific treatment regimen. The primary endpoint is the complete response rate. Secondary endpoints include safety, organ preservation rate (for rectal cancer only), R0 resection rate, surgical complications, treatment compliance, 3-year survival, and quality of life (QoL) score.

Conditions

  • Locally Advanced Colorectal Cancer

Interventions

  • SHR-1701Drug

    1800mg d1 q3w

  • SHR-8068Drug

    280mg,C1D1

  • Short-course radiotherapyRadiation

    25Gy/5Fx

  • XELOX (Capecitabine and Oxaliplatin)Drug

    Oxaliplatin: 130mg/m2 d1 q3w Capecitabine: 1000mg/m2 bid d1-14 q3w

  • PD-L1 antibodyDrug

    1200mg d1 q3w

  • cetuximab βDrug

    250mg/m2 d1, 500mg/m2 d8 q3w

  • HRS-7058Drug

    200mg bid

  • HRS-4642Drug

    500mg d1, 1200mg d8 q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response (CR) rate: rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.Time frame: 1 month after the surgery or 1 year after the decision of W&W.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.